Great article-abt the same as the one I read yesterday.
If I recall, late in 2008 or early 2009. ACT was noted as having 270 patents addressing various aspects of sc's. Many have been used to collect royalties from other sc companies-GERN for one. This was their source of income unil other major investors were approached.
The late Mr.Caldwell hinted in his last pr that additional and exciting info would be coming in Jan as well as throughout 2011. The issue of blood platelets is one while I believe the nxt pr will address heart desease.
Correct me if I'm wrong. Either way, the company is destined to remain at the forefront of the sc industry.
The researchers believe that platelets that are produced in this way could rapidly find their way into clinics, because they do not contain any genetic material, which largely eliminates the risk of introducing cancerous tumours into the recipient.
I'm glad I got in last week. Will add more each month. This stock over time should deliver tremendous returns, IMO!
I like the way this small company operates. It is amazing how investor friendly they are. When these geniuses discuss their findings I sense the intellectual property is protected such that long-term revenues will accrue to our share value.
This is big....go ACTC,,,,now I see why the bashers are working overtime...lol...they are scared to death...O well,sorry about your luck...you wont keep it down today...ACTC is on the move and the shorts will get smoked today...I feel bad for those that get sucked in by these clowns.